Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesLasofoxifene for the prevention and treatment of postmenopausal osteoporosis
Therapeutics and Clinical Risk Management, 10/16/09
Lewiecki ME – In postmenopausal women with low or normal bone mineral density (BMD), lasofoxifene increased BMD at the lumbar spine and hip and reduced bone turnover markers compared with placebo. In women with postmenopausal osteoporosis, lasofoxifene increased BMD, reduced bone turnover markers, reduced the risk of vertebral and nonvertebral fractures, and decreased the risk of estrogen receptor–positive breast cancer. In postmenopausal women with low bone mass, lasofoxifene improved the signs and symptoms of vulvovaginal atrophy. Clinical trials show that lasofoxifene is generally well tolerated with mild to moderate adverse events that commonly resolve even with drug continuation. Lasofoxifene has been associated with an increase in the incidence of venous thromboembolic events, hot flushes, muscle spasm, and vaginal bleeding.
Related Articles
Combination of Two Medications Help Postmenopausal Women with Osteoporosis
MedLinePlus, 10/30/09
Relevance Score: 68%
Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis
Journal of Clinical Endocrinology and Metabolism, 11/18/09
Relevance Score: 67%
Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Relevance Score: 67%
Bazedoxifene acetate: A novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis
Drugs of Today, 11/05/09
Relevance Score: 67%
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density
Journal of Bone and Mineral Research, 10/30/09
Relevance Score: 67%
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Developments in factor Xa inhibitors for the treatment of thromboembolic disorders
Medicinal Research Reviews, 12/09/09
Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol
Therapeutics and Clinical Risk Management, 12/09/09
Pharmacotherapy of diabetic foot osteomyelitis
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor